Tag Archives: biotech

Atossa Genetics Inc (NASDAQ:ATOS) hasn’t had a good 2017 so far. The company is currently trading for around $0.50 a share, down 65% on its 2017 open price. Over the last couple of days, however, Atossa has picked up a little bit of strength,...

On May 23, 2017, Protalix Biotherapeutics Inc (NYSEMKT:PLX) announced that it’s poised to present data from its lead cystic fibrosis (CF) study at the upcoming European Cystic Fibrosis Society Conference. On the back of the news, the...

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) has taken a hit on its most recent announcement, with the company currently trading at a close to 10% discount to its session open pricing. The decline comes on the back of the news that management...

Back on May 10, we published this piece asking the question: Is The Elite Pharmaceuticals Inc (OTCMKTS:ELTP) Data About To Hit Press? The data we were referring to was from a bioequivalent study of its lead development outside, an abuse-deterrent...

ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) has not had a great 2017. The company is down close to 40% year to date and trades at a more than 70% discount to its January highs. The surfacing of stock manipulation claims that hit press in...

Pernix Therapeutics Holdings Inc (NASDAQ:PTX) took a hit last week when the company announced its first quarter 2017 financials. During a subsequent conference call, however, management was able to ease sentiment a little, and Pernix will kick...

INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF) taken a bit of a dip since we last looked at the company, and currently trades for a little over $0.44 a share – around 35% off early April highs. This is a company that has picked up quite a lot...

Pulmatrix Inc (NASDAQ:PULM) reported earlier this month that it has picked up an additional patent related to its lead development program – PUR0200 in chronic obstructive pulmonary disease (COPD). It adds to a list of a number of already...

Neovasc Inc (US) (NASDAQ:NVCN) just put out its first-quarter earnings, and the company has taken a bit of a hit on the release. At last close, shares went for $1.43 a piece – a more than 15% decline on the company’s prerelease pricing....

Endonovo Therapeutics Inc (OTCMKTS:ENDV) currently trades for $0.06 a share. That’s a close to 35% discount on April highs. Against a backdrop of share price decline, this is a company that’s moving towards a number of key catalysts,...

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter